Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.

Baran Y, Saydam G.

J Blood Med. 2012;3:139-50. doi: 10.2147/JBM.S29132. Epub 2012 Nov 16.

PMID:
23180974
[PubMed]
Free PMC Article
2.

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.

Bitencourt R, Zalcberg I, Louro ID.

Rev Bras Hematol Hemoter. 2011;33(6):470-5. doi: 10.5581/1516-8484.20110124.

PMID:
23049365
[PubMed]
Free PMC Article
3.

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

Lima LM, Arellano M, Holloway S, Shepard M, McMillan S, Khoury HJ.

J Blood Med. 2010;1:221-5. doi: 10.2147/JBM.S7158. Epub 2010 Sep 10.

PMID:
22282699
[PubMed]
Free PMC Article
4.

Nilotinib: a novel, selective tyrosine kinase inhibitor.

Blay JY, von Mehren M.

Semin Oncol. 2011 Apr;38 Suppl 1:S3-9. doi: 10.1053/j.seminoncol.2011.01.016. Review. Erratum in: Semin Oncol. 2011 Jun;38(3):467.

PMID:
21419934
[PubMed - indexed for MEDLINE]
Free PMC Article
5.
6.

Targeted inhibition of kinases in cancer therapy.

Baker SJ, Reddy EP.

Mt Sinai J Med. 2010 Nov-Dec;77(6):573-86. doi: 10.1002/msj.20220. Review.

PMID:
21105121
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review.

Jabbour E, Cortes J, Kantarjian H.

Core Evid. 2010 Jun 15;4:207-13.

PMID:
20694077
[PubMed]
Free PMC Article
8.

Metabolism considerations for kinase inhibitors in cancer treatment.

Duckett DR, Cameron MD.

Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1175-93. doi: 10.1517/17425255.2010.506873. Review.

PMID:
20684746
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.

Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J.

Br J Haematol. 2010 Aug;150(3):303-12. doi: 10.1111/j.1365-2141.2010.08245.x. Epub 2010 Jun 10. Erratum in: Br J Haematol. 2011 Nov;155(3):409.

PMID:
20553275
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

Nair RR, Tolentino J, Hazlehurst LA.

Biochem Pharmacol. 2010 Sep 1;80(5):602-12. doi: 10.1016/j.bcp.2010.04.003. Epub 2010 Apr 9. Review.

PMID:
20382130
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.

Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH.

Haematologica. 2010 Mar;95(3):388-97. doi: 10.3324/haematol.2009.016063.

PMID:
20207846
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Effects of nilotinib on regulatory T cells: the dose matters.

Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Götz M, Bunjes D, Schmitt M.

Mol Cancer. 2010 Jan 29;9:22. doi: 10.1186/1476-4598-9-22.

PMID:
20113470
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.

Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F.

Drug Des Devel Ther. 2009 Sep 21;3:89-101.

PMID:
19920925
[PubMed]
Free PMC Article
14.

Development and targeted use of nilotinib in chronic myeloid leukemia.

Fava C, Kantarjian H, Cortes J, Jabbour E.

Drug Des Devel Ther. 2009 Feb 6;2:233-43.

PMID:
19920910
[PubMed]
Free PMC Article
15.

Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.

Stec R, Grala B, Maczewski M, Bodnar L, Szczylik C.

J Exp Clin Cancer Res. 2009 Oct 7;28:134. doi: 10.1186/1756-9966-28-134. Review.

PMID:
19811659
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.

Martinelli G, Iacobucci I, Soverini S, Palandri F, Castagnetti F, Rosti G, Baccarani M.

Biologics. 2007 Jun;1(2):121-7.

PMID:
19707322
[PubMed]
Free PMC Article
17.

New therapeutic approaches for advanced gastrointestinal stromal tumors.

Somaiah N, von Mehren M.

Hematol Oncol Clin North Am. 2009 Feb;23(1):139-50, x. doi: 10.1016/j.hoc.2008.12.004. Review.

PMID:
19248977
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems.

Radhakrishnan ML, Tidor B.

J Chem Inf Model. 2008 May;48(5):1055-73. doi: 10.1021/ci700452r. Epub 2008 May 27.

PMID:
18505239
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.

Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC.

J Biol Chem. 2008 Mar 28;283(13):8601-10. doi: 10.1074/jbc.M707934200. Epub 2008 Jan 26.

PMID:
18223253
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Jagani Z, Singh A, Khosravi-Far R.

Biochim Biophys Acta. 2008 Jan;1785(1):63-84. Epub 2007 Oct 16. Review.

PMID:
17980712
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk